ACADIA price target raised to $42 from $28 at Piper Jaffray Piper Jaffray raised its price target for ACADIA Pharmaceuticals to $42 citing the company's pipeline progress following its Q4 results. The firm keeps an Overweight rating on the stock.
ACADIA names Steve Davis president, CEO ACADIA Pharmaceuticals announced that its Board of Directors has appointed Steve Davis as President and CEO. Davis has been serving as ACADIA's Interim Chief Executive Officer since March 2015. Davis has also been appointed to the ACADIA Board of Directors.